Sensei Biotherapeutics acquires Faeth Therapeutics and raises $200M in Series B financing

Sensei Biotherapeutics completed the acquisition of Faeth Therapeutics on February 17, 2026, issuing 10.5M Series B Preferred shares to Faeth shareholders and simultaneously raising $200M from investors. The transaction significantly expands the company's pipeline and provides substantial capital for development and operations.